Cargando…
Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
INTRODUCTION: Demographic and disease characteristics may impact response to psoriasis therapies. The objective of this study is to explore the safety and efficacy profile of secukinumab in North American (NA) versus non-NA patients with moderate to severe psoriasis. METHODS: Data were pooled from f...
Autores principales: | Pariser, David, Frankel, Ellen, Schlessinger, Joel, Poulin, Yves, Vender, Ronald, Langley, Richard G., Meng, Xiangyi, Guana, Adriana, Nyirady, Judit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825316/ https://www.ncbi.nlm.nih.gov/pubmed/29218492 http://dx.doi.org/10.1007/s13555-017-0211-4 |
Ejemplares similares
-
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
por: Menter, Alan, et al.
Publicado: (2016) -
Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
por: Kircik, Leon, et al.
Publicado: (2016) -
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
por: Adsit, Sandra, et al.
Publicado: (2017) -
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
por: Adsit, Sandra, et al.
Publicado: (2017) -
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2017)